Format

Send to

Choose Destination
Breast Cancer Res. 2018 Nov 20;20(1):144. doi: 10.1186/s13058-018-1066-z.

Statin drugs to reduce breast cancer recurrence and mortality.

Beckwitt CH1,2,3, Brufsky A4, Oltvai ZN1,5, Wells A6,7,8,9,10,11.

Author information

1
Department of Pathology, University of Pittsburgh, Pittsburgh, 15231, PA, USA.
2
University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15231, USA.
3
Pittsburgh VA Health System, Pittsburgh, 15240, PA, USA.
4
Magee-Women's Hospital of Pittsburgh, 300 Halket St., Pittsburgh, 15213, PA, USA.
5
Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, 15231, PA, USA.
6
Department of Pathology, University of Pittsburgh, Pittsburgh, 15231, PA, USA. wellsa@upmc.edu.
7
Department of Bioengineering, University of Pittsburgh, Pittsburgh, 15231, PA, USA. wellsa@upmc.edu.
8
Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, 15231, PA, USA. wellsa@upmc.edu.
9
University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15231, USA. wellsa@upmc.edu.
10
Pittsburgh VA Health System, Pittsburgh, 15240, PA, USA. wellsa@upmc.edu.
11
Magee-Women's Hospital of Pittsburgh, 300 Halket St., Pittsburgh, 15213, PA, USA. wellsa@upmc.edu.

Abstract

Epidemiologic studies have, variably, shown the concomitant use of statin drugs to be beneficial to cancer outcomes. Statin drugs have been FDA approved for three decades for the treatment of high cholesterol and atherosclerotic coronary artery disease and are widely used. This has engendered studies as to their influence on concomitant diseases, including cancers. In this context, statin use has been correlated, variably, with a decrease in deaths from breast cancer. However, there is no extant model for this effect, and the extent of efficacy is open to question.The overarching goal of this article is to communicate to the reader of the potential of statins to reduce breast cancer progression and mortality. This is the use as a secondary prevention measure, and not as a therapy to directly counter active cancer. First, salient aspects of statin pharmacology, as relates to cardiovascular disease, will be discussed. Second, the basic and clinical research studies that investigate statin usage in breast cancer will be presented. Additionally, statin effects in other cancer types will be included for context. Finally, proposals for future basic and clinical research studies to determine the role of statins in breast cancer management will be presented.

KEYWORDS:

Breast cancer; Lipophilicity; Metastasis; Prenylation; Secondary prevention; Statins

PMID:
30458856
PMCID:
PMC6247616
DOI:
10.1186/s13058-018-1066-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center